|
| Using a gluconeogenesis-targeted kinome screening approach combined with transcriptome analyses, scientists uncovered Nemo-like kinase as a potent suppressor of hepatic gluconeogenesis (HGP). [Cell Metabolism] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reprogrammed hepatocytes from a mouse model of hereditary tyrosinemia type 1 into expandable CdHs and successfully corrected the disease-causing mutation using both adenine base editors and prime editors. [Cell Stem Cell] |
|
|
|
| Scientists generated a CRISPR base-edited hepatoma cell line harboring the c.1267C>T variant. These cells replicated the secreted abnormalities seen in serum N-glycosylation, and a portion of the mutant protein appeared to relocate to a distinct, non-golgi compartment, possibly endoplasmic reticulum exit sites. [American Journal of Human Genetics] |
|
|
|
| Investigators designed supramolecular nanofibers self-assembled by compound 1, which could strongly activate the hepatocyte growth factor precursor and initiate hepatocyte growth factor–Met signaling. [ACS Applied Materials & interfaces] |
|
|
|
| Mechanistic studies revealed that Tspan5 promoted cell migration and tumor metastasis by increasing the enzymatic maturation of ADAM10 and activating Notch signaling via the increase of the cleavage of the Notch1 receptor catalyzed by the γ‐secretase complex. [Molecular Oncology] |
|
|
|
| Scientists showed that morphine could inhibit hepatocellular carcinoma (HCC) cell proliferation. They further showed that DEAD-box helicase 49 (DDX49 ) was up-regulated in HCC tumors, and that knocking down the DDX49 gene decreases tumor formation in vivo and in vitro, as well as reduces tumor metastasis in vivo. [Aging] |
|
|
|
| The impact of platelets on the sorafenib and resminostat drug effects in hepatocellular carcinoma cells was explored. In contrast to sorafenib, resminostat triggered an anti-proliferative response in hepatocellular carcinoma cell lines independent of platelets. [Scientific Reports] |
|
|
|
| Researchers employed a mouse model of carbon tetrachloride induced-acute liver injury with clodronate-induced macrophage depletion to clarify the impact of liver injury on liver metabolism and recovery dynamics of metabolic function and liver zonation during regeneration. [Scientific Reports] |
|
|
|
| Scientists used physiologically based pharmacokinetic modeling to understand the translational accuracy of data generated with human embryonic kidney (HEK)293 cells overexpressing the hepatic uptake transporters OATP1B1/3 with and without plasma, while accounting for transporter expression. [Drug Metabolism and Disposition] |
| |
|
|
|
| The recent genetic analysis uncovered a distinctive driver gene landscape in precancerous lesions, arguing a discontinuous process at early hepatocellular carcinoma development. [Journal of Human Genetics] |
|
|
|
|
| POSEIDON was a Phase III trial of AstraZeneca’s IMFINZI® plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the first-line treatment of patients with Stage IV non-small cell lung cancer. [Business Wire, Inc.] |
|
|
|
| NovoBiome, Inc. launched to revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis. [NovoBiome, Inc. (Globenews Wire, Inc.)] |
|
|
|
|
| November 29 – December 1, 2021 Barcelona, Spain |
|
|
|
|
|
| Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| The Griffin Institute – Harrow, United Kingdom |
|
|
|
| University of Wisconsin-Madison – Madison, Wisconsin, United States |
|
|
|
| University of Illinois – Chicago, Illinois, United States |
|
|
|
| Deep Genomics, Inc. – Toronto, Ontario, Canada |
|
|
|
|